Company: MDCXW
Filing Date: 2025-09-15
Form Type: 424B3
Source: 0001062993-25-015613
Chunk: 2

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-15
Form: 424B3
Chunk 2
---
 Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On September 12, 2025, Medicus Pharma Ltd. (the "Company") announced that James Quinlan, Chief Financial Officer of the Company, will be taking a medical leave of absence from the Company commencing on such date. In connection with Mr. Quinlan's medical leave of absence, Carolyn Bonner was appointed as acting Chief Financial Officer ("Acting CFO") of the Company. Ms. Bonner, 41, will also continue to serve as President of the Company, a role she has held since September 2023. Ms. Bonner will not receive any additional compensation for her service as Acting CFO and has not entered into any agreement with respect to her service as Acting CFO.

Prior to joining the Company Ms. Bonner was the President & CEO of Parkway Clinical Laboratories (2019 to 2023), a College of American Pathologist accredited diagnostic company, serving healthcare providers across the United States. Ms. Bonner was also the Director of Corporate Development at Building Beyond BRIC Investment Fund (2019 to 2023) where she was extensively involved in fundraising, marketing, and assisting with back office operations from May 2009 to December 2011. Previously Ms. Bonner was the Director of Business Development at Parkway Clinical Laboratories ("PCL"), where she delivered client guided customization of PCL services and creative corporate partnerships. Carolyn also simultaneously served as Director of Corporate Development for Rosetta Genomics, a publicly traded Israeli biotech company, the parent company of PCL, from July 2008 to May 2009. Ms. Bonner started her career in 2006 as a sales executive at Lakewood Pathology (now called PLUS Diagnostics), which is owned and operated by Water Street Healthcare Partners, a Chicago based private equity fund. Ms. Bonner has a B.A. focused in marketing from West Chester University.

There are no family relationships between Ms. Bonner and any director or executive officer of the Company pursuant to Item